Biocon Biologics Signs an In-License Agreement with Just – Evotec Biologics

Biocon Biologics Signs a In-License Agreement with Just – Evotec Biologics for its Biosimilar Assets


  • Biocon Biologics will perform all end-to-end development activities, IND filing, manufacturing and commercialization post-regulatory approval in its own authorized global markets for assets and will utilize Just – Evotec Biologics’ expertise in process development domain mainly in optimized manufacturability
  • Just – Evotec Biologics to receive license fee plus development, regulatory and commercial milestone payments. The focus of the agreement is to expand Biocon Biologics’ biosimilar portfolio with the addition of Just – Evotec’s pre-clinical candidates and utilizing their late-stage development, manufacturing and commercial capabilities plus technology for further development
  • Biocon Biologics has pipeline of 28 candidates including 11 with Mylan some with Sandoz and focusses to develop therapies in diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases

Click here to­ read full press release/ article | Ref: Evotec | Image: Twitter